Most Recent Articles by Kathy Boltz, PhD
Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to the drugs that target these mutations.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
Biopsies are the most costly tool associated with lung cancer diagnosis, according to research.
A risk stratification model, based on lymph node characteristics, can confirm a negative classification of lung cancer with a high level of confidence.
The relatively high incidence of mouth squamous cell cancer in nonsmokers without obvious causes has been noted in studies, with nonsmokers having a higher proportion of cancers occur on the edge of the tongue.
More Articles by Kathy Boltz, PhD
- Study investigating advanced MRI scans to detect prostate cancer set to begin
- TNF-alpha inhibitors associated with uveal melanoma
- Improved survival in pediatric umbilical cord transplants for hematologic cancers
- Most internet sites on prostate cancer disagree with expert panel's recommendations
- Radiation exposure linked to aggressive thyroid cancers
- A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia
- Early palliative care can cut hospital readmissions for cancer patients
- ONA Interview: Breaking the barriers to effective palliative care
- Fluorescent tattoos may improve self-esteem in patients receiving radiotherapy for breast cancer
- Cancer prehabilitation: One step toward improved outcomes
- Exercise therapy benefits breast cancer survivors
- CT lung screening appears cost-effective
- Collaboration yields new methods to treat tumors with antennas
- Classifying gene mutations in neuroblastoma may point to improved treatments
- International study shows wide differences in 5-year survival rates across the globe
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|